As the world prepares to observe World Tuberculosis (TB) Day, Faberco Life Sciences Incorporated is proud to share a significant advancement in the country’s fight against drug-resistant tuberculosis (DR-TB). The Health Technology Assessment (HTA) Council of the Philippines has issued a preliminary positive recommendation for the potential public financing of Pretomanid 200 mg tablet through the Department of Health (DOH) and/or PhilHealth.
This recommendation marks a pivotal step toward improving access to innovative, life-saving treatments for patients suffering from highly drug-resistant TB, a condition that poses one of the greatest challenges to TB eradication efforts globally and locally.
Pretomanid, developed as part of new, shorter, and more effective DR-TB treatment regimens, is designed to offer a safer alternative to existing therapies that are often lengthy, toxic, and difficult to complete. The HTA Council’s initial recommendation recognizes the clinical value of Pretomanid in delivering better patient outcomes and the importance of public health programs in supporting access to such critical interventions.
Faberco Life Sciences, in partnership with Viatris for the Philippine market, has taken a leading role in bringing Pretomanid to the country. This collaboration reflects Faberco’s
enduring mission to address unmet medical needs by making innovative treatments more accessible to Filipino patients.
With the HTA Council’s preliminary recommendation, the pathway is opening for Pretomanid to be included in government treatment programs, potentially transforming the lives of patients battling DR-TB.
While the fight against TB continues, this progress gives renewed hope to patients, healthcare providers, and public health stakeholders alike. Faberco Life Sciences remains steadfast in its advocacy for innovation, health equity, and collaborative action to end TB in the Philippines.